» Articles » PMID: 29697822

Renal Angiomyolipoma in Patients with Tuberous Sclerosis Complex: Findings from the TuberOus SClerosis Registry to Increase Disease Awareness

Abstract

Background: Renal angiomyolipoma occurs at a high frequency in patients with tuberous sclerosis complex (TSC) and is associated with potentially life-threatening complications. Despite this frequency and severity, there are no large population-based cohort studies. Here we present baseline and follow-up data of the international TuberOus SClerosis registry to increase disease Awareness (TOSCA) with an aim to provide detailed clinical characteristics of renal angiomyolipoma among patients with TSC.

Methods: Patients of any age with a documented clinic visit for TSC within 12 months or who were newly diagnosed with TSC before participation in the registry were eligible. Data specific to renal angiomyolipoma included physical tumour characteristics (multiple, bilateral, lesion size and growing lesions), clinical signs and symptoms, and management. The effects of age, gender and genotype on the prevalence of renal angiomyolipoma were also evaluated.

Results: Renal angiomyolipoma was reported in 51.8% of patients at baseline, with higher frequency in female patients (57.8% versus 42.2%). The median age at diagnosis was 12 years. Prevalence of angiomyolipoma was higher in patients with TSC2 compared with TSC1 mutations (59.2% versus 33.3%, P < 0.01). Of the 1031 patients with angiomyolipoma at baseline, multiple lesions were reported in 88.4% and bilateral in 83.9% of patients, while the size of angiomyolipoma was >3 cm in 34.3% of patients. Most patients were asymptomatic (82%). Frequently reported angiomyolipoma-related symptoms included bleeding, pain, elevated blood pressure and impaired renal function. Embolization and mammalian target of rapamycin inhibitors were the two most common treatment modalities.

Conclusions: The TOSCA registry highlights the burden of renal angiomyolipoma in patients with TSC and shows that renal manifestations are initially asymptomatic and are influenced by gender and genotype. Furthermore, the occurrence of significant problems from angiomyolipoma in a minority of younger patients suggests that surveillance should begin in infancy or at initial diagnosis.

Citing Articles

Tuberous sclerosis complex-associated kidney disease in children.

Marlais M, Mekahli D Pediatr Nephrol. 2025; .

PMID: 39814976 DOI: 10.1007/s00467-024-06642-9.


Rare genetic interstitial lung diseases: a pictorial essay.

Borie R, Berteloot L, Kannengiesser C, Griese M, Cazes A, Crestani B Eur Respir Rev. 2024; 33(174).

PMID: 39537246 PMC: 11558537. DOI: 10.1183/16000617.0101-2024.


Spontaneous angiomyolipoma rupture: A case of hemorrhagic shock and urgent embolization.

Awashra A, Sawaftah Z, Milhem F, Hamdan D, Odah A, Sawafta A Radiol Case Rep. 2024; 19(12):6286-6291.

PMID: 39387028 PMC: 11461921. DOI: 10.1016/j.radcr.2024.09.034.


Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland.

Vasseghi M, Behan C, Connolly A, Cunningham D, Dempsey E, Flynn C J Rare Dis (Berlin). 2024; 3(1):24.

PMID: 39165678 PMC: 11330946. DOI: 10.1007/s44162-024-00049-8.


Circulating biomarkers of kidney angiomyolipoma and cysts in tuberous sclerosis complex patients.

Rubtsova V, Chun Y, Kim J, Ramirez C, Jung S, Choi W iScience. 2024; 27(7):110265.

PMID: 39027368 PMC: 11255849. DOI: 10.1016/j.isci.2024.110265.


References
1.
Kingswood J, dAugeres G, Belousova E, Ferreira J, Carter T, Castellana R . TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients. Orphanet J Rare Dis. 2017; 12(1):2. PMC: 5217262. DOI: 10.1186/s13023-016-0553-5. View

2.
Bhatt J, Richard P, Kim N, Finelli A, Manickavachagam K, Legere L . Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs >4cm Can Be Offered Active Surveillance as an Initial Management Strategy. Eur Urol. 2016; 70(1):85-90. DOI: 10.1016/j.eururo.2016.01.048. View

3.
Kingswood J, Bissler J, Budde K, Hulbert J, Guay-Woodford L, Sampson J . Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study. Nephron. 2016; 134(2):51-58. DOI: 10.1159/000448293. View

4.
Rakowski S, Winterkorn E, Paul E, Steele D, Halpern E, Thiele E . Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. Kidney Int. 2006; 70(10):1777-82. DOI: 10.1038/sj.ki.5001853. View

5.
Wataya-Kaneda M, Tanaka M, Hamasaki T, Katayama I . Trends in the prevalence of tuberous sclerosis complex manifestations: an epidemiological study of 166 Japanese patients. PLoS One. 2013; 8(5):e63910. PMC: 3656843. DOI: 10.1371/journal.pone.0063910. View